Innate Pharma and its Chairman and CEO Mondher Mahjoubi, MD, have made the development of lacutamab, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody the first priority for the French biotech, which is building a pipeline of antibodies against cancer. [Jean-Marie Huron]
Lacutamab has progressed to the Phase II TELLOMAK trial (NCT03902184), which is assessing the antibody's efficacy and safety in patients with advanced cutaneous T-cell lymphoma (CTLC). Lacutamab is under study in patients with mycosis fungoides and two other CTLC subtypes . . .
